Ascelia Pharma AB (publ) (ACE) - Total Liabilities

Latest as of September 2025: Skr22.01 Million SEK ≈ $2.37 Million USD

Based on the latest financial reports, Ascelia Pharma AB (publ) (ACE) has total liabilities worth Skr22.01 Million SEK (≈ $2.37 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Ascelia Pharma AB (publ) strategic investment ratio to see how much of total assets are deployed in long-term investments.

Ascelia Pharma AB (publ) - Total Liabilities Trend (2016–2024)

This chart illustrates how Ascelia Pharma AB (publ)'s total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see Ascelia Pharma AB (publ) balance sheet assets.

Ascelia Pharma AB (publ) Competitors by Total Liabilities

The table below lists competitors of Ascelia Pharma AB (publ) ranked by their total liabilities.

Company	Country	Total Liabilities
Vantage Corp NYSE MKT:VNTG	USA	$8.17 Million
Hindusthan National Glass & Industries Limited NSE:HINDNATGLS	India	Rs37.16 Billion
Yorkton Equity Group Inc V:YEG	Canada	CA$152.03 Million
KB SPAC 6 KQ:208640	Korea	₩2.13 Billion
FATFISH GROUP LTD. F:1JU	Germany	€29.99 Million
Nanotech Indonesia Global Tbk PT JK:NANO	Indonesia	Rp42.12 Billion
Bonk, Inc. NASDAQ:BNKK	USA	$5.10 Million
Inter-Delta Tbk JK:INTD	Indonesia	Rp3.69 Billion

Liability Composition Analysis (2016–2024)

This chart breaks down Ascelia Pharma AB (publ)'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See Ascelia Pharma AB (publ) balance sheet independence to measure how much of total assets are equity-financed.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric	Value	Description
Current Ratio	3.60	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	0.19	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.16	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Ascelia Pharma AB (publ)'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Ascelia Pharma AB (publ) (2016–2024)

The table below shows the annual total liabilities of Ascelia Pharma AB (publ) from 2016 to 2024.

Year	Total Liabilities	Change
2024-12-31	Skr61.98 Million ≈ $6.67 Million	+386.32%
2023-12-31	Skr12.74 Million ≈ $1.37 Million	-66.21%
2022-12-31	Skr37.71 Million ≈ $4.06 Million	+46.97%
2021-12-31	Skr25.66 Million ≈ $2.76 Million	+32.82%
2020-12-31	Skr19.32 Million ≈ $2.08 Million	+46.75%
2019-12-31	Skr13.16 Million ≈ $1.42 Million	+16.03%
2018-12-31	Skr11.35 Million ≈ $1.22 Million	+156.73%
2017-12-31	Skr4.42 Million ≈ $475.55K	+58.33%
2016-12-31	Skr2.79 Million ≈ $300.36K	--

About Ascelia Pharma AB (publ)

ST:ACE Sweden Biotechnology

Market Cap

$8.55 Million

Skr79.42 Million SEK

Market Cap Rank

#27545 Global

#602 in Sweden

Share Price

Skr0.63

Change (1 day)

+9.25%

52-Week Range

Skr0.48 - Skr3.85

All Time High

Skr900.24